On Thursday, Biogen Inc (BIIB) stock saw a decline, ending the day at $164.89 which represents a decrease of $-0.90 or -0.54% from the prior close of $165.79. The stock opened at $165 and touched a ...

Biogen on Tuesday pledged a return to earnings growth this year after three years of slippage, but that wasn’t enough to keep investors from sending the share price down 4.9% in morning trading.

Based in Cambridge, MA, Biogen Inc. is one of the world’s leading biotechnology companies, which focuses on developing innovative therapies for treating serious neurological and ...

We expect Biogen BIIB to beat expectations when it reports first-quarter 2023 results on Ap 25, before market open. In the last reported quarter, the company delivered an earnings surprise of 15.38%.

Dr Yacine Hadjiat is global head of Biogen Digital Health Solutions. He sat down with pharmaphorum at Frontiers Health 2022 in Milan to discuss how his group approaches digital innovation around ...

Cambridge, Massachusetts-based Biogen Inc. (BIIB) discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. With a market cap of $26.6 bi ...

Biogen agreed to pay Denmark’s Forward Pharma $1.25 billion upfront, and under a licence agreement may pay future royalties from Tecfidera dependent on ongoing patent cases in US and EU.

Biogen shares fell more than 16% in early trading on Friday after quarterly earnings results that beat on profits but missed on revenues. Also, the biotech giant lowered its forecast for full-year ...

Biogen Inc. (BIIB) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook ...

For the quarter ended September 2024, Biogen Inc. (BIIB) reported revenue of $2.47 billion, down 2.6% over the same period last year. EPS came in at $4.08, compared to $4.36 in the year-ago quarter.